Literature DB >> 11264163

Basis of hematopoietic defects in platelet-derived growth factor (PDGF)-B and PDGF beta-receptor null mice.

W E Kaminski1, P Lindahl, N L Lin, V C Broudy, J R Crosby, M Hellström, B Swolin, D F Bowen-Pope, P J Martin, R Ross, C Betsholtz, E W Raines.   

Abstract

Platelet-derived growth factor (PDGF)-B and PDGF beta-receptor (PDGFR beta) deficiency in mice is embryonic lethal and results in cardiovascular, renal, placental, and hematologic disorders. The hematologic disorders are described, and a correlation with hepatic hypocellularity is demonstrated. To explore possible causes, the colony-forming activity of fetal liver cells in vitro was assessed, and hematopoietic chimeras were demonstrated by the transplantation of mutant fetal liver cells into lethally irradiated recipients. It was found that mutant colony formation is equivalent to that of wild-type controls. Hematopoietic chimeras reconstituted with PDGF-B(-/-), PDGFR beta(-/-), or wild-type fetal liver cells show complete engraftment (greater than 98%) with donor granulocytes, monocytes, B cells, and T cells and display none of the cardiovascular or hematologic abnormalities seen in mutants. In mouse embryos, PDGF-B is expressed by vascular endothelial cells and megakaryocytes. After birth, expression is seen in macrophages and neurons. This study demonstrates that hematopoietic PDGF-B or PDGFR beta expression is not required for hematopoiesis or integrity of the cardiovascular system. It is argued that metabolic stress arising from mutant defects in the placenta, heart, or blood vessels may lead to impaired liver growth and decreased production of blood cells. The chimera models in this study will serve as valuable tools to test the role of PDGF in inflammatory and immune responses. (Blood. 2001;97:1990-1998)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264163     DOI: 10.1182/blood.v97.7.1990

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

Review 1.  Cellular precursors of the coronary arteries.

Authors:  Ramón Muñoz-Chápuli; Mauricio González-Iriarte; Rita Carmona; Gerardo Atencia; David Macías; José María Pérez-Pomares
Journal:  Tex Heart Inst J       Date:  2002

2.  Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice.

Authors:  Koichi Kozaki; Wolfgang E Kaminski; Jingjing Tang; Stan Hollenbach; Per Lindahl; Carol Sullivan; Jin-Chen Yu; Keith Abe; Paul J Martin; Russell Ross; Christer Betsholtz; Neill A Giese; Elaine W Raines
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

3.  Engineering of tooth-supporting structures by delivery of PDGF gene therapy vectors.

Authors:  Qiming Jin; Orasa Anusaksathien; Sarah A Webb; Marie A Printz; William V Giannobile
Journal:  Mol Ther       Date:  2004-04       Impact factor: 11.454

Review 4.  Role of platelet-derived growth factors in physiology and medicine.

Authors:  Johanna Andrae; Radiosa Gallini; Christer Betsholtz
Journal:  Genes Dev       Date:  2008-05-15       Impact factor: 11.361

5.  The role of myeloid cell-derived PDGF-B in neotissue formation in a tissue-engineered vascular graft.

Authors:  Ekene Onwuka; Cameron Best; Andrew Sawyer; Tai Yi; Eric Heuer; Malik Sams; Matthew Wiet; Hong Zheng; Themis Kyriakides; Christopher Breuer
Journal:  Regen Med       Date:  2017-05-19       Impact factor: 3.806

6.  Platelet-Derived Growth Factor Delivery via Nanofibrous Scaffolds for Soft-Tissue Repair.

Authors:  Qiming Jin; Peter X Ma; William V Giannobile
Journal:  Adv Skin Wound Care       Date:  2010-01-01       Impact factor: 2.347

7.  Trophoblasts regulate the placental hematopoietic niche through PDGF-B signaling.

Authors:  Akanksha Chhabra; Andrew J Lechner; Masaya Ueno; Asha Acharya; Ben Van Handel; Yanling Wang; M Luisa Iruela-Arispe; Michelle D Tallquist; Hanna K A Mikkola
Journal:  Dev Cell       Date:  2012-03-01       Impact factor: 12.270

8.  HIF1α-induced PDGFRβ signaling promotes developmental HSC production via IL-6 activation.

Authors:  Sung-Eun Lim; Virginie Esain; Wanda Kwan; Lindsay N Theodore; Mauricio Cortes; Isaura M Frost; Sarah Y Liu; Trista E North
Journal:  Exp Hematol       Date:  2016-10-15       Impact factor: 3.084

9.  Reduced mural cell coverage and impaired vessel integrity after angiogenic stimulation in the Alk1-deficient brain.

Authors:  Wanqiu Chen; Yi Guo; Espen J Walker; Fanxia Shen; Kristine Jun; S Paul Oh; Vincent Degos; Michael T Lawton; Tarik Tihan; Dimitrios Davalos; Katerina Akassoglou; Jeffrey Nelson; John Pile-Spellman; Hua Su; William L Young
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12-13       Impact factor: 8.311

10.  Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Farhad Ravandi; Susan O'Brien; Deborah Thomas; Gabriela Vidal-Senmache; William Wierda; Steven Kornblau; Jorge Cortes
Journal:  Cancer       Date:  2009-06-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.